XGEVA® as a treatment for giant cell tumor of bone (GCTB)
XGEVA® is a prescription medicine used to treat adults and some skeletally mature adolescents with giant cell tumor of bone that cannot be surgically removed (unresectable) or when surgery is likely to result in severe morbidity, such as loss of limbs or joint removal.
XGEVA® is the first and only FDA-approved treatment for giant cell tumor of bone (GCTB).1
GCTB: a rare, aggressive benign tumor2,3
GCTB is a benign, or non-cancerous, tumor. There are approximately 300 to 800 new cases of GCTB per year in the US.4 Even though it is not cancerous, GCTB can cause damage in the area in which it occurs. It can lead to the breakdown of bone and expand into the surrounding soft tissues.3
How XGEVA® works in GCTB
Bone is constantly being built and broken down in your body. Cells that break down bones are called osteoclasts [os-tee-uh-klasts]. A chemical, called RANK Ligand (RANKL), sends signals to the osteoclasts that cause them to increase the breakdown of your bone.5
GCTB acts in a similar way to osteoclasts. RANK Ligand sends signals to the GCTB that cause it to grow and lead to bone breakdown.1-3 XGEVA® works on the RANKL to stop the activity of osteoclasts and GCTB and slows down bone breakdown.1-3
RANK Ligand, or RANKL, attaches to GCTB.
RANKL sends signals to GCTB that causes it to grow and damage the bone.
XGEVA® binds to RANKL and slows bone breakdown and GCTB growth.1
XGEVA® is given as a single shot under the skin into the upper arm, upper thigh, or abdomen.1
The recommended dose of XGEVA® is 120 mg administered every 4 weeks, with additional 120 mg doses on Days 8 and 15 of the first month of therapy.1
Calcium and vitamin D should be administered as necessary to treat or prevent hypocalcemia.1